Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Good evening, here are the coronavirus updates you need to know tonight.

Top headlines:

  1. Health Canada has approved Pfizer’s coronavirus vaccine.
  2. Britain says people with history of significant allergic reactions should avoid thePfizer vaccine
  3. Claims the province was slow to bring in tighter COVID-19 rules is “Alberta bashing:” Kenney

In Canada, there have been at least 435,330 cases reported. In the last week 45,554 new cases were announced, 8% more than the previous week. There have also been at least 350,010 recoveries and 12,983 deaths. Health officials have administered more than 13,894,770 tests.

Story continues below advertisement

New deaths in Canada, Dec. 9

The Globe and Mail

Worldwide, there have been at least 68,225,587 cases confirmed and 1,556,834 deaths reported.

Sources: Canada data is compiled from government websites, Johns Hopkins and COVID-19 Canada Open Data Working Group; international data is from Johns Hopkins University.


Coronavirus explainers: Coronavirus in maps and charts Lockdown rules and reopening Mask-wearing rules Back to school guide Essential resources


Photo of the day

A person walks past the Pfizer headquarters building in Manhattan on Wednesday.

CARLO ALLEGRI/Reuters


Coronavirus in Canada


In Ottawa, Health Canada announced it approved a COVID-19 vaccine produced by Pfizer and BioNTech, with rollout set to begin next week.

  • Health studies have found the vaccine, which requires two doses three weeks apart to be effective, to be safe.
  • Canada is just the third country – after Bahrain and Britain – to approve a fully tested coronavirus shot.
  • The first doses of the vaccine are set to be administered beginning next week, with hospital and nursing home staff at the front of the line.
  • The Prime Minister previously said his objective is to have most Canadians vaccinated by September of 2021.

Also today, Pfizer reported that documents related to its vaccines had been “unlawfully accessed” in a cyberattack on Europe’s medicines regulator.

Also in Ottawa, the government unveiled the specifics of a program to allow asylum seekers who have been working in a specific list of health care related professions to apply for permanent residency starting Dec. 14.

Vaccine controversy: A Canadian biomanufacturing company says it can still produce a COVID-19 vaccine for Canada if asked, but the federal government says it has already picked the best candidates. In Question Period, the Conservative Leader asked why the Prime Minister ignored advice from his own task force to seek a made-in-Canada vaccine.

Story continues below advertisement


Coronavirus around the world

  • In Britain, two National Health Service workers reported anaphylactoid reactions associated with receiving the vaccine, prompting a warning from the country’s medicine regulator for people with a history of significant allergic reactions to avoid the drug.
  • Kim Jong Un’s sister, Kim Yo Jong, lambasted South Korean Foreign Minister Kang Kyung-wha for questioning North Korea’s claim to be free from coronavirus, warning of potential consequences for the comments.

Coronavirus and business

The Bank of Canada left its key policy rate unchanged today at a record-low 0.25 per cent.

  • The central bank made its final scheduled interest rate decision of 2020, balancing the near-term economic risks from the second wave of coronavirus with the arrival of vaccines to alleviate the pandemic.
  • The bank also made no changes to its quantitative easing program, under which it has committed to buying at least $4-billion a week of Canadian government bonds.

Also today: Federal tourism marketing strategies will shift toward promoting travel within regions first, and across the country second, the government said today. Federal funding has shifted away from attracting foreign visitors to Canada for the foreseeable future, as COVID-19 suppresses travel.

And: Dollarama announces a new round of pandemic pay as it reported higher earnings and increased its dividend to shareholders.


Globe opinion


More reporting


Information centre

Sources: Canada data are compiled from government websites, Johns Hopkins University and COVID-19 Canada Open Data Working Group; international data are from Johns Hopkins.

What are we missing? Email us: audience@globeandmail.com. Do you know someone who needs this newsletter? Send them to our Newsletters page.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the authors of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies